The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Publications

Export 11032 results:
[ Author(Asc)] Title Type Year
Filters: Filter is   [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
M
Makri, E. S., Goulas A., & Polyzos S. A. (2021).  Sodium-glucose co-transporter 2 inhibitors in nonalcoholic fatty liver disease.. Eur J Pharmacol. 907, 174272.
Makri, E., Kita M., Goulas A., Papaioannidou P., Efstathiadou Z. A., Adamidou F., et al. (2020).  Comparative effectiveness of glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors on noninvasive indices of hepatic steatosis and fibrosis in patients with type 2 diabetes mellitus.. Diabetes Metab Syndr. 14(6), 1913-1919.
Makri, E., Cholongitas E., & Tziomalos K. (2016).  Emerging role of obeticholic acid in the management of nonalcoholic fatty liver disease.. World J Gastroenterol. 22(41), 9039-9043.
Makri, E. S., Evripidou K., & Polyzos S. A. (2024).  Circulating leptin in patients with nonalcoholic fatty liver disease-related liver fibrosis: a systematic review and a meta-analysis.. J Gastroenterol Hepatol.
Makri, E., Orfanidou M., Makri E. S., Goulas A., Terpos E., & Polyzos S. A. (2024).  Circulating Ferritin in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis.. J Clin Exp Hepatol. 14(3), 101353.
Makras, P., Papapoulos S. E., Polyzos S. A., Appelman-Dijkstra N. M., & Anastasilakis A. D. (2020).  The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosis.. Bone. 138, 115478.
Makras, P., Anastasilakis A. D., Polyzos S. A., Bisbinas I., Sakellariou G. T., & Papapoulos S. E. (2011).  No effect of rosuvastatin in the zoledronate-induced acute-phase response.. Calcif Tissue Int. 88(5), 402-8.
Makras, P., Polyzos S. A., Anastasilakis A. D., Terpos E., Kanakis G., Schini M., et al. (2012).  Serum osteoprotegerin, RANKL, and Dkk-1 levels in adults with Langerhans cell histiocytosis.. J Clin Endocrinol Metab. 97(4), E618-21.
Makras, P., Yavropoulou M. P., Polyzos S. A., Papapoulos S. E., Georgakopoulou D., Papatheodorou A., et al. (2023).  The relationship between length of denosumab treatment for postmenopausal osteoporosis and serum TRAcP5b measured six months after the last injection.. Osteoporos Int.
Makras, P., Babis G. C., Chronopoulos E., Karachalios T., Kazakos K., Paridis D., et al. (2020).  Experience gained from the implementation of the fracture liaison service in Greece.. Arch Osteoporos. 15(1), 12.
Makras, P., Polyzos S. A., & Anastasilakis A. D. (2016).  Letter to the Editor: Bone Turnover as a Potential Determinant of Bone Mineral Density Increase Following the Transition From Bisphosphonates to Either Denosumab or Zoledronic Acid.. J Clin Endocrinol Metab. 101(9), L89-90.
Makras, P., Polyzos S. A., Papatheodorou A., Kokkoris P., Chatzifotiadis D., & Anastasilakis A. D. (2013).  Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosis.. Clin Endocrinol (Oxf). 79(4), 499-503.
Makras, P., Polyzos S. A., Anastasilakis A. D., Terpos E., Papatheodorou A., & Kaltsas G. A. (2012).  Is serum IL-17A a useful systemic biomarker in patients with Langerhans cell histiocytosis?. Mol Ther. 20(1), 6-7.
Makras, P., Appelman-Dijkstra N. M., Papapoulos S. E., van Wissen S., Winter E. M., Polyzos S. A., et al. (2021).  The duration of denosumab treatment and the efficacy of zoledronate to preserve bone mineral density after its discontinuation.. J Clin Endocrinol Metab.
Makedou, K., Kourtis A., Gkiomisi A., Toulis K. A., Mouzaki M., Anastasilakis A. D., et al. (2011).  Oxidized low-density lipoprotein and adiponectin levels in pregnancy.. Gynecol Endocrinol. 27(12), 1070-3.
Makedou, K. G., Mikhailidis D. P., Makedou A., Iliadis S., Kourtis A., Vavatsi-Christaki N., et al. (2009).  Lipid profile, low-density lipoprotein oxidation and ceruloplasmin in the progeny of families with a positive history of cardiovascular diseases and/or hyperlipidemia.. Angiology. 60(4), 455-61.
Makedou, K., Iliadis S., Gogou M., Kara E., & Papageorgiou G. (2017).  Sesame oil: an ex vivo study of properties against oxidation of plasma low-density lipoproteins and total serum lipoproteins. . Hellenic Journal of Cardiology . 58(2), 
Makedou, K. (2018).  Epigenetics and Childhood Obesity: From Uterus to Childhood. Annals of Pediatric Research. 2(2), 
Makedou, K. (2012).  Hypertension: A Serious Complication in Pregnancy (Editorial). Current Hypertension Reviews. 8(2), 
Makedou, K., Iliadis S., Kara E., Gogou M., Feslikidis T., & Papageorgiou G. (2012).  Honey and its protective role against oxidation of human low density lipoproteins and total serum lipoproteins.. Hippokratia. 16(3), 287.
Makedou, K., & Kourtis A. (2016).  Emergencies of Endocrinology in Pregnancy and Labor. Obstetrics & Gynecology International Journal. 4(6), 
Makedou, K. G., Vagdatli E., Patziarela E., Konstantinidou V., Poimenidou E., & Lymperaki E. (2018).  Total Antioxidant Capacity, Haematological and Coagulation Parameters after Orthodox Christian Fast.. Open Access Maced J Med Sci. 6(2), 284-286.
Makedos, A., Goulis D. G., Papanikolaou A., & Panidis D. (2010).  Serum high-sensitivity C-reactive protein and homocysteine changes during hormonal therapy in women with polycystic ovary syndrome: a prospective, matched study.. Angiology. 61(6), 595-601.
Makedos, A., Mandala E., Ilonidis G., & Makedos G. (2011).  Diagnosis of peritoneal tuberculosis: random involvement of gynecologists.. Eur J Obstet Gynecol Reprod Biol. 159(2), 482.
Makavos, G., Κairis C., Tselegkidi M-E., Karamitsos T., Rigopoulos A. G., Noutsias M., et al. (2019).  Hypertrophic cardiomyopathy: an updated review on diagnosis, prognosis, and treatment.. Heart Fail Rev. 24(4), 439-459.

Pages

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.